Skip to Content


Hematology & Oncology (Subscribe)

Links

|< < > >|

Current Trends in Lung Cancer and Head & Neck Cancer

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/230

The Current Trends in Lung Cancer and Head & Neck Cancer series of regional meetings is designed to update practicing oncologists and thoracic surgeons on recent advances in the management of lung and head & neck cancers. Attendees will be updated on long-term data on adjuvant chemotherapy in early-stage disease; in the metastatic setting, the maintenance approach to therapy will be discussed. Advances in multimodality treatment strategies for stage III NSCLC, including the integration of targeted agents, will be addressed. Updates on efforts to customize lung cancer therapy based on pharmacogenomic patient characteristics will be provided. This symposium will cover in detail current data on the use of agents that block the activity of the EGFR and VEGF pathways to treat NSCLC as well as novel therapies in development for lung cancer. Current approaches to the treatment of patients with SCLC, including novel cytotoxic and targeted agents, will also be presented. This lecture series will also review recent clinical trials in head and neck cancer investigating induction chemotherapy for locally advanced disease. Studies exploring the integration of targeted agents, including EGFR and angiogenesis inhibitors, into the treatment of head and neck cancer will be presented. These meetings will provide extensive opportunity to interact with the faculty, including ample time for questions as well as extensive case-based discussion sessions. This educational program is directed toward medical oncologists, radiation oncologists, and thoracic surgeons specializing in lung and/or head and neck cancer. Nurses, physician assistants, fellows, and pharmacists in oncology who are interested in the treatment of lung and head and neck cancers are also invited to attend.

Review It Rate It Bookmark It

Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/185

The Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies symposium is intended to update physicians, advanced practice nurses, pharmacists, physician assistants, and other health care providers on advances in lymphoma, leukemia, multiple myeloma, myelodysplastic syndromes, and supportive care. Through didactic presentations, pro/con debates, and case studies, the audience will participate in discussions concerning the diagnosis and management of a variety of hematologic malignancies. In addition to the main session, small-group breakout sessions will address advanced practice nursing, pharmacy, and hematopathology. This educational program is directed toward medical oncologists, hematologists, nurses, nurse practitioners, physician assistants, and pharmacists interested in the treatment of hematologic malignancies. Other health care professionals who are interested in the treatment of hematologic malignancies are also invited to attend.

Review It Rate It Bookmark It

Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/183

Presented by Physicians’ Education Resource in Conjunction With Duke University School of Medicine The Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies symposium is intended to update physicians, advanced practice nurses, pharmacists, physician assistants, and other health care providers on advances in lymphoma, leukemia, multiple myeloma, myelodysplastic syndromes, and supportive care. Through didactic presentations, pro/con debates, and case studies, the audience will participate in discussions concerning the diagnosis and management of a variety of hematologic malignancies. In addition to the main session, small-group breakout sessions will address advanced practice nursing, pharmacy, and hematopathology. This educational program is directed toward medical oncologists, hematologists, nurses, nurse practitioners, physician assistants, and pharmacists interested in the treatment of hematologic malignancies. Other health care professionals who are interested in the treatment of hematologic malignancies are also invited to attend.

Review It Rate It Bookmark It

Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/652

This activity is presented by Physicians’ Education Resource in conjunction with Duke University Division of Cellular Therapy and Duke Oncology Network. The Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies symposium provides a unique opportunity for medical oncologists, hematologists, physician assistants, nurse practitioners, nurses, and other health care professionals to obtain practical updates and expert views on management of and controversies in hematologic malignancies in order to increase knowledge and apply new data to practice. Topics include: Simultaneous sessions in acute myeloid leukemia Therapy of elderly patients, timing of transplant, and cognitive changes from therapy Insights into classification, diagnosis, and prognosis Debates on current issues Role of active therapy in secondary leukemia Splenectomy versus thrombopoietic agents in immune thrombocytopenic purpura First- versus second-generation tyrosine kinase inhibitors as induction therapy for chronic myeloid leukemia New induction regimens for indolent non-Hodgkin lymphoma Role of maintenance therapy following transplant in multiple myeloma

Review It Rate It Bookmark It

Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/182

Oncology CME-Certified Congress The Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that underlie the optimal management of early-stage breast cancer. A significant emphasis on case discussion and available adjuvant and neoadjuvant treatment options will provide a forum to discuss and debate the controversies concerning and practical applicability of evolving clinical trial findings. Other topics pertaining to diagnosis, staging, breast cancer subtypes, risk assessment, toxicity management, and survivorship issues will also be addressed. The purpose of this congress is to provide an update on the latest advances in the management of early-stage breast cancer, addressing key areas of controversy. Target Audience This educational program is directed toward medical, surgical, and radiation oncologists practicing in the community or at academic institutions. Fellows, nurses, physician assistants, and pharmacists with an interest in the treatment of breast cancer are also invited to attend. Learning Objectives At the conclusion of this congress, you should be able to: Review new diagnostic and management insights into hereditary breast cancers Describe the principles of state-of-the-art imaging and surgical techniques as well as radiation therapy and apply them to the treatment of patients with breast cancer Review the latest data on preoperative therapies and surgical and radiation therapy management strategies Review and debate the clinical utility and implications of novel genomic and pathologic diagnostic tools to subset breast cancer Assess the utility of algorithms and genomic tools to assess recurrence risk and predict benefit from adjuvant chemotherapy, hormonal therapy, and HER2-targeted therapy for individual patients Evaluate novel cytotoxic and biologic agents and their utility in neoadjuvant or adjuvant regimens Evaluate data from recent adjuvant chemotherapy clinical trials and use them to optimize and individualize treatment for patients with early-stage breast cancer Analyze the efficacy of adjuvant chemotherapy by breast cancer subtype Review the latest clinical data on adjuvant endocrine therapy, including up-front versus switching strategies and extended therapy with selective estrogen receptor modulators and aromatase inhibitors Apply key data on bisphosphonates from trials assessing outcomes on bone health and recurrence risk to the management of patients in defined clinical scenarios Discuss the recent clinical trial data that provide the underpinnings for state-of-the-art adjuvant and neoadjuvant systemic therapy for breast cancer Discuss the mechanisms of action of emerging chemotherapeutic, endocrine, and biologic agents; the rationale for and efficacy of novel combination regimens; and their potential place in therapy Guide patients to promising clinical trials...

Review It Rate It Bookmark It

Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/182

The Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that underlie the optimal management of early-stage breast cancer. A significant emphasis on case discussion and available adjuvant and neoadjuvant treatment options will provide a forum to discuss and debate the controversies concerning and practical applicability of evolving clinical trial findings. Other topics pertaining to diagnosis, staging, breast cancer subtypes, risk assessment, toxicity management, and survivorship issues will also be addressed. The purpose of this congress is to provide an update on the latest advances in the management of early-stage breast cancer, addressing key areas of controversy.

Review It Rate It Bookmark It

Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/182

The Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that underlie the optimal management of early-stage breast cancer. A significant emphasis on case discussion and available adjuvant and neoadjuvant treatment options will provide a forum to discuss and debate the controversies concerning and practical applicability of evolving clinical trial findings. Other topics pertaining to diagnosis, staging, breast cancer subtypes, risk assessment, toxicity management, and survivorship issues will also be addressed. The purpose of this congress is to provide an update on the latest advances in the management of early-stage breast cancer, addressing key areas of controversy. Follow us on Twitter @ControBrCa www.twitter.com/ControBrCa

Review It Rate It Bookmark It

Eighth International Congress on Gastrointestinal Malignancies

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/371

The Eighth International Congress on Gastrointestinal Malignancies is dedicated to an in-depth discussion of the best care options for the comprehensive management of patients with early- or advanced-stage gastrointestinal malignancies, including hepatocellular carcinoma and pancreatic, gastroesophageal, and colorectal cancers. This highly interactive meeting will include didactic lectures, debates, and case-based clinical presentations to provide a forum for discussion as well as context for the integration of recent advances in the clinical and surgical management of these malignancies. The optimal integration of biologic agents, such as antiangiogenic and EGFR-targeted agents, into current standard regimens across multiple lines of therapy in these diseases will be addressed and debated. The role of surgery and perioperative therapeutic regimens, including chemotherapy and multimodality therapies, in the treatment of patients with early-stage disease will also be discussed. Current controversies in the application of emerging clinical trial findings to daily practice will be debated by expert opinion leaders. Practical strategies to minimize treatment-related toxicities, such as neuropathy and skin toxicities, will also be reviewed. Furthermore, the genetics and molecular biology underlying prognostic and predictive assays, novel therapeutics on the horizon, and relevant high-priority clinical trials that are currently enrolling patients will be discussed. Target Audience This educational program is directed primarily toward medical oncologists, surgical oncologists, radiation oncologists, gastroenterologists, internal medicine and primary care physicians, basic researchers and investigators, practitioners, and fellows interested in liver, pancreatic, gastric, esophageal, and colorectal cancers. Nurses, physician assistants, and other individuals interested in the treatment of gastrointestinal malignancies and colorectal cancer are also welcome to attend. Learning Objectives At the conclusion of this congress, you should be able to: Explain the rationale and targets of therapy at the molecular level for novel agents in the treatment of gastroesophageal cancers Assess combination chemotherapy and chemoradiation therapy approaches in the neoadjuvant and perioperative settings for the treatment of gastric and esophageal cancer Analyze the efficacy and safety of chemotherapy regimens alone or combined with targeted agents in advanced gastroesophageal cancer Evaluate the impact of targeted therapies on the treatment of hepatocellular carcinoma Assess the potential impact of antiangiogenic and EGFR-targeted agents on the efficacy of conventional chemotherapy and outcome of patients with pancreatic cancer Discuss current concepts in the pathobiology and treatment of pancreatic cancer Interpret current issues and clinical data regarding surgical and chemotherapeutic treatment strategies for pancreatic cancer Assess biomarkers, such as KRAS, that are predictive of tumor response or toxicity profile for targeted and cytotoxic agents Utilize assay results to individualize treatment selection for patients with metastatic CRC Evaluate novel prognostic assays for their ability to assess recurrence risk in patients with localized CRC Assess recurrence risk factors for patients with stage II CRC to identify patients at increased risk of disease recurrence Evaluate standard of care adjuvant therapy options for individualized management of early-stage CRC Evaluate current standard of care therapy options for individualized management of metastatic CRC, including the use of antiangiogenic or EGFR-targeted agents in the first-line setting and beyond Assess differences in the efficacy and safety of fluoropyrimidine formulations as indicated by patient characteristics Evaluate the role of cytotoxic chemotherapies, targeted therapies, and surgery in the management of liver-only metastases in patients with CRC Identify specific adverse events associated with antiangiogenic or EGFR-targeted agents Review patient exposure to prior therapy with agents used in CRC and possible predisposition to treatment-related adverse events Evaluate treatment options, such as intermittent or continuous dosing, for patients experiencing acute and cumulative neuropathy due to platinum-containing therapy Identify advances in supportive care for treatment-associated toxicities in patients with CRC and other gastrointestinal malignancies Describe the rationale of investigational diagnostic and therapeutic strategies for gastrointestinal malignancies Assess the role of investigational treatment regimens and novel agents for gastrointestinal malignancies Identify appropriate patients for enrollment in clinical trials

Review It Rate It Bookmark It

Eighth International Congress on Targeted Therapies in Cancer

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/242

The Eighth International Congress on Targeted Therapies in Cancer has been designed to provide participants with cutting-edge information on novel targeted anticancer therapies now being developed, highlighting the mechanisms of action of and the most current clinical data on those agents. The congress will detail the multiple signaling pathways that are disrupted in cancer as well as novel targeted approaches that specifically affect aberrant signaling in tumor cells, such as the mammalian target of rapamycin (mTOR) pathway; agents targeting the tumor microenvironment, including vascular disrupting agents and angiopoietin as well as inhibitors of vascular endothelial growth factor; agents targeting molecules involved in developmental pathways; and agents that harness the body’s own immune system to combat neoplastic disease. Clinical applications of novel imaging techniques will be discussed. The congress will also cover novel therapeutic and drug discovery platforms and will explore efforts to use combinatorial approaches to fine-tune the effectiveness of monoclonal antibodies. Furthermore, a preview of new agents on the horizon for specific tumor types will be presented. As the burgeoning field of targeted therapies continues to evolve, there is a clear need for physicians to be continuously updated on the most recent efficacy and safety data on these new classes of agents. The congress will use didactic learning and panel discussions to provide an educational program that allows physicians to keep abreast of these rapid developments.

Review It Rate It Bookmark It

Eighth International Congress on the Future of Breast Cancer

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showAccommodations/id/5/conference_id/139

The Eighth International Congress on the Future of Breast Cancer is an international educational and scientific meeting that focuses on the clinical implications of breast cancer genetic and phenotypic subtyping. New data and promising studies that provide information about how to optimally individualize breast cancer therapy will be the highlights of the congress. Key topics in breast cancer diagnosis and management will be discussed and controversial issues debated in multiple faculty panel discussions. Strategies for optimizing the use of endocrine therapy, conventional chemotherapy, and agents targeting HER2 or angiogenic pathways will be discussed. Evolving diagnostic approaches to identify the driving mutations or pathways in breast cancers will be thoroughly discussed, along with the therapies targeting those mutations. Controversial management issues in the surgical and radiotherapeutic management of breast cancer will be discussed and debated. The format will include didactic sessions from thought leaders, question-and-answer panel discussions, and ample time for participant interaction with faculty. This educational program is directed toward medical, surgical, and radiation oncologists practicing in the community or at academic institutions. Fellows, nurses, physician assistants, and pharmacists with an interest in the treatment of breast cancer are also invited to attend.

Review It Rate It Bookmark It

Eighth International Symposium on Melanoma and Other Cutaneous Malignancies

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/651

The Eighth International Symposium on Melanoma and Other Cutaneous Malignancies will continue the well-established commitment to provide participants with a multidisciplinary and comprehensive overview of the contemporary care of patients with these diseases. Topics to be highlighted at this symposium include updates in disease prevention, current and emerging diagnostic technologies, genetic testing, adjuvant therapy, emerging therapies for regional disease, and systemic therapies, such as immunotherapies and targeted therapies for metastatic melanoma and other cutaneous malignancies. These topics and their implications for practice will be presented and unresolved issues debated by leading experts in the treatment of the different cutaneous tumor types, with ample time allotted for questions from the audience. Given the recent dramatic progress in therapy options, this interactive symposium will also extensively explore practical considerations for the management of patients with advanced cutaneous malignancies in an interactive case-based discussion session with the faculty, who will provide expert insights into optimal patient management strategies in the new therapeutic landscape. Throughout the symposium, participants will also learn about currently accruing high-priority trials and relevant patient eligibility criteria in order to enhance enrollment on trials evaluating novel therapeutic regimens in both the adjuvant and advanced-disease settings for melanoma and other cutaneous malignancies.

Review It Rate It Bookmark It

Emerging Strategies in Women’s Cancers

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/332

The Emerging Strategies in Women’s Cancers symposium has been designed to provide participants with cutting-edge information on the screening, diagnosis, and treatment of malignancies affecting women worldwide. This forum will focus on clinical and translational research in the areas of breast, ovarian, and cervical cancers, discussing not only standards of care and current guidelines, but also highlighting the most promising novel chemotherapeutics and targeted agents. Advances in diagnosis, prevention strategies, and risk assessment will also be addressed, particularly with regards to the role of tumor biology and genetics. For patients with breast cancer, increased cytotoxic and targeted therapeutic options require physicians to stay updated on the optimal incorporation of novel therapies into standard treatment regimens. The role of endocrine therapy in prevention and treatment of breast cancer is also expanding, further complicating the benefit-risk ratios for patients with hormone receptor-positive disease. Controversies in the combined modality approaches and chemotherapeutic management of ovarian carcinomas and issues revolving around prevention and treatment strategies for cervical cancer will also be discussed. The conference will use didactic lectures and case-based discussions to provide participants with ample opportunities to learn from and interact with key opinion leaders in the field.

Review It Rate It Bookmark It

Expert Perspectives: Integrating New Data Into Best Practices for Breast Cancer

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/590

The Expert Perspectives: Integrating New Data Into Best Practices for Breast Cancer satellite symposium focuses on 3 controversial aspects of breast cancer therapy, highlighting recent advances in molecular assay–based risk assessment for node-negative and node-positive disease, therapeutic approaches to early-stage and advanced triple-negative breast cancer, and optimal strategies for the management of patients with early-stage or metastatic HER2+ breast cancer. Leading experts in the field of breast cancer will present cases illustrating areas of debate followed by their perspectives on the interpretation and application of recent clinical data and guidelines in order to increase the ability of participants to apply new data to their clinical practice and improve patient care. Not an official event of the ASCO Breast Cancer Symposium. Not sponsored or endorsed by any of the co-sponsoring organizations of the ASCO Breast Cancer Symposium.

Review It Rate It Bookmark It

Focus on Myeloma and Plasma Cell Disorders

http://www.imedex.com

Chairs: Bart Barlogie, MD, PhD and Elias J. Anaissie, MD

Review It Rate It Bookmark It

Hematology and Medical Oncology CME Best Practices Audio Video from George Washington University Med

http://www.apolloaudiobooks.com/t.php?p=GW_Hematology_and_Medical_Oncology_CME_Directory

Start Date: 01/31/2011
End Date: 01/31/2014

Description: Comprehensive Review of Best Practices available in DVD video, audio CD and other formats. Good for up to 55 hours of CME credits. Cost is approximately. $1395 to $2095

Review It Rate It Bookmark It

Hollywood Arcade: Metastatic Breast Carcinoma

http://www.apolloaudiobooks.com/t.php?p=Hollywood_Arcade_Interactive_Oncology_Game_CME_Directory

Start Date: 02/01/2011
End Date: 02/01/2014

Description: Earn up to 9 Oncology CME credits from Hollywood Arcade: Metastatic Breast Carcinoma - The FREE Online, Interactive Oncology CME Game. Available in Online-Interactive Arcade Game and approximately FREE.

Review It Rate It Bookmark It

Institutional Insights in Multiple Myeloma

http://www.multiplemyeloma.org/medical_programs

Institutional Insights in Multiple Myeloma, provides practical insight on how to apply the latest advances in diagnosis, prognosis, frontline therapy, treatments for relapsed/refractory disease, management of bone disease, and supportive care. Educational Objectives: At the completion of this program, the participants should be able to: 1. Identify the prognostic indicators and diagnostic approaches to multiple myeloma. 2. Discuss the latest advances in stem cell transplantation, treatments for bone disease, and supportive care management. 3. Describe the role and appropriate use of novel treatments for multiple myeloma throughout the disease progression.

Review It Rate It Bookmark It

Journal CME Watch General Medicine

http://www.apolloaudiobooks.com/t.php?p=Journal_Watch_General_Medicine_CME_Directory

Start Date: 02/01/2011
End Date: 02/01/2014

Description: General Medicine Audio updates based on cutting edge medicine from over 60 of the best medical journals. Earn up to 48 hours CME credit annually and available in online as MP3, via mail as CD or cassette tape for approximately $249 to $393.

Review It Rate It Bookmark It

Lymphoma & Myeloma 2008

http://www.imedex.com

Chair: Morton Coleman, MD Co-Chairs: John P. Leonard, MD, Ruben Niesvisky, MD, and Richard R. Furman, MD

Review It Rate It Bookmark It

Mayo Clinic Hematology/Oncology Reviews

http://www.mayo.edu/cme

Mayo Clinic Hematology/Oncology Reviews is a comprehensive postgraduate course designed to provide the busy practicing hematologist/oncologist with practical new developments. Didactic presentations will be case-based. Attendees will leave with up-to-date, practical information which will have immediate clinical application.

Review It Rate It Bookmark It

Mayo Clinic Hematology/Oncology Reviews

http://www.mayo.edu/cme/hematology-oncology/index.html

Mayo Clinic Hematology/Oncology Reviews is a comprehensive postgraduate course designed to provide the busy practicing hematologist/oncologist with practical new developments. Didactic presentations will be case-based. Attendees will leave with up-to-date, practical information which will have immediate clinical application.

Review It Rate It Bookmark It

Medical Oncology Best Practices CME Audio Video

http://www.apolloaudiobooks.com/t.php?p=Medical_Oncology_Best_Practices_CME_Directory

Start Date: 02/01/2011
End Date: 02/01/2014

Medical Oncology Best Practices from George Washington University Medical Center available in DVD video, audio CD and other formats. Good for up to 35 hours of CME credits. Cost is approximately $1195 to $1695.

Review It Rate It Bookmark It

Merging and Redirecting Traffic: Exploiting the Biology of Renal Cell Carcinoma

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/264

The Merging and Redirecting Traffic: Exploiting the Biology of Renal Cell Carcinoma symposium is designed to update physicians on the latest information regarding the optimal treatment of patients with renal cell carcinoma using targeted agents and how to integrate this information into everyday practice. The symposium focuses on the current standard of care for patients with newly diagnosed disease, the optimal sequence of targeted agents in individualized therapy, the potential role of combining therapeutics in maximizing patient benefit, and emerging therapeutic agents and how they will be integrated into the treatment algorithm. This symposium will also address current options for the treatment of advanced disease following progression on previous targeted agents. This educational program is directed toward medical, surgical, and radiation oncologists with an interest in the treatment of kidney cancer. Fellows, oncology physician assistants, oncology nurses, and research nurses with an interest in the treatment of patients with kidney cancer are also invited to attend.

Review It Rate It Bookmark It

Ninth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/530

The Ninth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that underlie the optimal management of early-stage and locally advanced breast cancer. The congress will include an in-depth discussion of the increasing number of breast cancer subtypes that challenge oncologists. A significant emphasis on case discussions and new data supporting adjuvant and neoadjuvant treatment options will provide a forum for discussion of the practical applicability of evolving clinical trial findings. Other topics pertaining to predictive biomarkers, staging, risk assessment, toxicity management, and survivorship will also be addressed. The purpose of this congress is to provide an update on the latest advances in the management of early-stage and locally advanced breast cancer and to address key areas of controversy concerning treatment in those settings.

Review It Rate It Bookmark It

Ninth International Congress on Genitourinary Malignancies

http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/261

The Ninth International Congress on Genitourinary Malignancies will provide a comprehensive review of current therapeutic standards for all aspects of the treatment of kidney, bladder, and prostate cancers, including clinical and molecular disease characterization, prevention, prognostication, multimodality management of disease, and novel therapeutic agents. Interactive panel discussions and case-based scenarios will provide context for the interpretation of presented data from clinical trials. Faculty recommendations and interactive tumor board–style discussion will aid in transitioning treatment standards to individualized care in the practice setting. Participants will be able to integrate the latest advances in the treatment of genitourinary malignancies into their daily practice as well as discuss future directions in research and clinical trials. This educational program is directed toward medical, surgical, and radiation oncologists; urologists; internal medicine and primary care physicians; and basic research investigators. Fellows, oncology nurses, physician assistants, and pharmacists interested in the treatment and management of patients with genitourinary malignancies are also invited to attend.

Review It Rate It Bookmark It

|< < > >|